05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals, pharmaceutical preparations and substances, and therapeutic agents for the prevention and treatment of diseases and disorders, namely, infectious diseases and diseases of the liver or kidney
2.
BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
Provided herein are bicyclic quinones, e.g., a compound of Formula (A-I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a parasite disease.
Provided herein are bicyclic quinones, e.g., a compound of Formula (A-I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a parasite disease.
C07D 319/16 - Dioxanes-1, 4Dioxanes-1, 4 hydrogénés condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/4168 - 1,3-Diazoles ayant un atome d'azote lié en position 2, p. ex. clonidine
A61K 31/541 - Thiazines non condensées contenant d'autres hétérocycles
A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
C07D 311/04 - Benzo [b] pyrannes non hydrogénés dans le carbocycle
3.
ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
6.
BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
e.g.e.g., a compound of Formula (A-I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a parasite disease.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
Provided herein is a method of treating or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject ascorbic acid and a quinone compound, e.g., a compound of Formula (I).
Provided herein is a method of treating or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject ascorbic acid and a quinone compound, e.g., a compound of Formula (I).
Provided herein is a method of treating or alleviating one or more symptoms of a tumor in a subject, comprising intratumorally administering to the subject a therapeutically effective amount of ascorbic acid and a quinone compound
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NFκB-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K. Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of pancreatic cancer in a subject, comprising administering to the subject therapeutically effective amounts of (i) vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a vitamin K compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
19.
Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant
Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
